DiaMedica Therapeutics Inc. (DMAC) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Two Carlson Parkway
Minneapolis, MN 55447
United States of America (the)
Phone
763 612 6755
Website
Sector
Healthcare
Industry
Biotechnology
Employees
27
First IPO Date
August 03, 2012
| Name | Title | Pay | Year Born |
| Dietrich John Pauls | President, Chief Executive Officer & Director | 1.07M | 1971 |
| Scott Kellen | Chief Financial Officer & Corporate Secretary | 609,870 | 1965 |
| Julie Krop | Chief Medical Officer | 675,668 | 1966 |
| Dominic R. Cundari | Chief Commercial Officer | 0 | 1951 |
| Ambarish Shah | Chief Technology Officer | 0 | N/A |
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.